

CEPI 3.0: Renewed Strategies for the 100 Days Mission


Dr. Claire Standley

Asia Centre for Health Security Webinar Series

16 July 2026

What is CEPI?

Coalition for Epidemic Preparedness Innovations



An international organization

Norway-based, with offices in Oslo, London, and Washington, DC

Our mission

To accelerate the development of vaccines against epidemic and pandemic threats

How CEPI works


Funded by 46 governments and philanthropies
Competitively disburses R&D and manufacturing awards

CEPI's unique and complementary role in the ecosystem


Connector, funder, source of global expertise, taking a whole-systems approach to pandemic preparedness



CEPI



Note: Vaccine development pathway is non-linear and not serial – parallel activities & feedback are continuous up and down value chain



A decade of innovation and proactive protection

2017 to present



30+
Funders



\$4.25 bn
Raised since 2017



470+
R&D partners collaborating
with CEPI

CEPI FIRSTS

Nipah



Advanced the **first ever** Nipah vaccine into **Phase 2** trials

Rift Valley fever



Advanced RVF vaccine into **Phase 2** trials

MERS



Advanced the **first ever** MERS vaccine into **Phase 2** trials

Lassa fever



Advanced the **first ever** Lassa virus vaccine into **Phase 2** trials

Chikungunya



First **licensed** Chikungunya vaccine


Innovations



Supported the **first medical product designed using AI** to be approved for any indication anywhere in the world.

CORONAVIRUSES

COVID-19



Supported **14** COVID-19 vaccine candidates

4 granted EUL

3 approved for domestic use

BPCV



World's leading funder of vaccine R&D, investing in 14 broadly protective coronavirus vaccine candidates

COVAX launched and co-led by CEPI



Nearly **2 billion** vaccines



Shipped to **146 countries**



2.7 million deaths averted in lower-income countries

FILOVIRUSES

Ebola



Supported generation of data to support expanded access and licensed vaccines

Marburg

10 DAYS

Supported Rwandan led response which deployed vaccine into a clinical trial

CEPI 1.0 to 3.0: building on nine years of learnings




Launched as an innovative coalition

Focused on addressing high-priority epidemic threats and platform technologies



Responded rapidly

Provided at-risk R&D funding; co-led COVAX and supported a portfolio of candidates



Inspired the 100 Days Mission

Mission was embraced by multiple governments, civil society and private sector



Invested in 100DM building blocks

Advanced priority pathogen vaccines, expanded knowledge of viral families, invested in rapid-response platforms, launched next-gen innovations



A new paradigm for epidemic and pandemic preparedness


CEPI has galvanized the world to embrace the “100 Days Mission”

CEPI’s Vision:


A world in which epidemics and pandemics are no longer a threat to humanity.

CEPI’s Mission:

Accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need




CEPI 3.0 (2027-2031): A Five-Year Strategy to Secure the Future





Integrated viral family approach to vaccine development

**Deliver response-ready
vaccines and investigational
reserves.**







*High-risk viral families and example pathogens within each family



Ready and available vaccine platforms

**Rapid-response vaccine
platforms and regulatory
readiness.**





Ready to activate networks and capabilities

**Exercise our global networks,
building, testing and
demonstrating 100 Days
Mission capabilities.**



Map of selected CEPI network partners

Cross-cutting themes and deliverables



Innovation & AI

- Embed innovation within sustainable platforms
- Leverage AI across the R&D and manufacturing value chain



Equitable Access

- Co-create end-to-end access roadmaps
- Use these roadmaps to convene early access discussions.
- Redesign equitable access for cross-cutting innovations



Regional Partnerships

- Strengthen strategic investments in country capabilities for clinical trials, testing and manufacturing
- Facilitate knowledge-sharing, co-creation and technical support
- Align with regional priorities



Biosecurity

- Embed biosecurity and biosafety principles
- Work with partners to strengthen the capabilities of frontline research institutions
- Ensure CEPI networks reinforce secure operations, trust and shared norms
- Strengthen engagement with the defence and security sectors

CEPI Biosecurity

- Enabled by generous support from Global Affairs Canada, CEPI launched a **biosecurity strategy** and implementation plan with a focus to “protect society from epidemic and pandemic threats, with an emphasis on **preventing accidental and deliberate misuse of pathogens associated with CEPI-sponsored research.**”
- CEPI recognises the need for 100 Days Mission capabilities to protect society, **no matter the origin of the outbreak** (natural, accidental or deliberate)



Priority #1

Strengthen biosafety and biosecurity risk identification, mitigation, and oversight by CEPI and encourage similar efforts by other life science research funders.



Priority #2

Enhance global biosafety and biosecurity capabilities of CEPI partners for achieving the 100 Days Mission safely and securely, and promote health-security partnerships.



Priority #3

Drive biosecurity and biosafety in support of equity.



Priority #4

Monitor and reduce emerging biotechnology and converging technology risks across CEPI's vaccine research, development, and manufacturing portfolio.



Priority #5

Accelerate biosafety and biosecurity innovation for vaccine research, development, and manufacturing.

Achieving the 100 Days Mission safely and securely



Embedding biosecurity and biosafety in **everyday practice** and building **emergency readiness** to prevent accidental and deliberate misuse of pathogens

(Biosecurity Strategy Priorities 1 & 2)



Catalysing **equitable and responsible participation** in the 100 Days Mission around the world by strengthening biosecurity and biosafety capabilities

(Biosecurity Strategy Priority 3)



Unleashing the benefits of **emerging technologies and innovation** to accelerate vaccine development while minimising biosecurity and biosafety risks

(Biosecurity Strategy Priorities 4 & 5)



CEPI's Biosecurity accomplishments

Sept 2024 - Sept 2025

INVESTMENT & RETURN



CAD 1M invested by Global Affairs Canada



Catalysed CAD 13.8M funding (2025–26)



ROI: 8:1 return (every CAD \$1 from Canada leveraged CAD \$8 from CEPI)


RISK REDUCTION & INNOVATION



Biosecurity integrated into CEPI's USD ~4B portfolio



Development of new biosecurity policy & procedures (2025)



Leading on development of biosecurity controls in CEPI's multimillion dollar AI vaccine-development platform

LOOKING AHEAD

- Scaling up global biosecurity capacity building
- Driving safe & secure progress toward the 100 Days Mission
- Strengthening risk reduction

STRATEGY & GLOBAL LEADERSHIP



Positioned CEPI as global leader in responsible biological innovation



First ever CEPI Biosecurity strategy launched (2024)



Developed and released implementation plan for CEPI's Biosecurity Strategy across 47 countries (2025–26)



CEPI as founding signatory of Bio Funders Compact (2024)

BUILDING BIOSECURITY CAPACITY



Established 9-member CEPI Biosecurity Department from 1 initial role



Permanent budget through 2026 - CEPI has now committed CAD 13.8M to biosecurity activities for 2025-2026



Biosecurity embedded in CEPI 3.0 strategy (from 2027)

RAPID CRISIS RESPONSE IN DRC



Supported CEPI-backed institutions/partners during M23 conflict (2025)



Secured pathogen samples in high-risk areas



Partnered with WHO, Africa CDC, LSHTM, Fondation Mérieux, US State Department and US CDC



New training & eLearning modules in English & French

STRENGTHENING PARTNERSHIPS



New MoU's with Munich Security Conference, Foreign Policy



New biosecurity partnerships with Africa CDC and Sentinel Bio



Elevated 100 Days Mission as part of global WMD non-proliferation agenda

CEPI is driving activities with a dual biosecurity-equity benefit



Biosecurity Emerging Leaders Declaration at the 61st Munich Security Conference

Taking Biological Threats Off The Table Through Next-Generation Global South Leadership

Pandemics—from the 1918 H1N1 influenza to COVID-19—have had a devastating impact on human lives, economies, and global security. Each outbreak reminds us that swift and coordinated action is essential: early intervention saves lives and prevents exponential spread.


The **100 Days Mission (100DM)** aims to develop medical countermeasures within 100 days of a newly identified biological threat, regardless of whether they arise naturally, accidentally, or deliberately. Reducing the window for pathogen spread is vital to national, regional, and global security, as it significantly lessens the impact on global health, security, and economies. The advancement of emerging technologies, such as Artificial Intelligence (AI), mRNA vaccine technology, and genomic sequencing, holds significant potential for achieving the 100DM. However, without responsible governance, these innovations may also pose unprecedented risks.

- **Responsible research is critical to enable the global collaboration required to achieve the 100 Days Mission.**
- When the global system neglects the interdependence of equity and biosecurity, we undermine both.

CEPI is:

- **Ensuring our biosecurity programmes have equity at the core** – including implementation of the oversight, capacity building (e.g. transparent, performance-based standards), mitigating risks of emerging technologies, supporting Global South leadership
- **Deepening awareness and understanding to drive progress** – including policy discussions about responsibility, funding and collaboration (e.g. World Health Summit, Munich Security Conference)

Biosecurity and the 100DM



Biosecurity and the 100DM


A range of biothreats in a dynamic geopolitical climate

Natural



Rwanda Marburg outbreak (2024)

Accidental



BSL-4 labs and national biorisk management score (2025)

Deliberate



Emerging and converging tech risk



Catalysing innovative partnerships in the dynamic geopolitical context


- Countries are reshaping national defense priorities and spending
- The **100 Days Mission delivers dual-benefit capabilities that can be leveraged by both health and defence to prepare for the full spectrum of infectious threats**
- CEPI is **strengthening its engagements with the defence** sector towards our joint goals to protect society, so we can leverage assets and expertise, and reach the 100 DM capabilities sooner



**MISSION ALIGNMENT
AND COMMITMENT
TO EQUITY**



**CROSS-SECTOR
COLLABORATION**



**NEUTRALITY AND
INDEPENDENCE**





**VALUES, HUMAN
RIGHTS AND RISK
ASSESSMENT**




**TRANSPARENCY AND
ACCOUNTABILITY**

CEPI 3.0 in action: Bundibugyo response

CEPI is pursuing a multi-track strategy to bring at least **two vaccine candidates** to Emergency Use Authorisation while **simultaneously investigating other countermeasures** for potential protection.



CEPI 3.0 in action: Bundibugyo response



CEPI 3.0 in action: Bundibugyo response


CEPI is also supporting **biosecurity equipment and materials**, leveraging our existing partnership with **Fondation Mérieux** and the **Institut National de Recherche Biomédicale**.

This support will also contribute to **safe and secure vaccine clinical trials**.



Fondation
Mérieux





Thank you!

CEPI